心肌无复流防治的最新研究进展(4)
[16] Wang L， Cheng Z， Gu Y， Peng D. Short-term effects of verapamil and diltiazem in the treatment of no reflow phenomenon： a meta-analysis of randomized controlled trials. Biomed Res Int 2015；2015：382086.
[17] Zhao YJ， Fu XH， Ma XX， et al. Intracoronary fixed dose nitroprusside via thrombus aspiration catheter for the prevention of the no-reflow phenomenon following primary percutaneous coronary intervention in acute myocardial infarction.Exp Ther Med 2013；6：479–84.
, 百拇医药
[18] Nazir SA， Khan JN， Mahmoud IZ， et al. The REFLO-STEMI trial comparing intracoronary adenosine， sodium nitroprusside and standard therapy for the attenuation of infarct size and microvascular obstruction during primary percutaneous coronary intervention： study protocol for a randomised controlled trial. Trials 2014；15：371.
[19] Akpek M，Sahin O，Sarli B，et al.Acute Effects of Intracoronary Tirofiban on No-Reflow Phenomena in Patients With ST-Segment Elevated Myocardial InfarctionUndergoing Primary Percutaneous Coronary Intervention[J].Angiology，2015，66(6)：560-567
, 百拇医药
[20] Iwakura J， Ito H， Okamura A， et al. Nicorandil treatment in patients with acute myocardial infarction： a meta-analysis. Circ J 2009；73：925–31.
[21] Cung TT， Morel O， Cayla G， et al. Cyclosporine before PCI in patients with acute myocardial infarction. N Engl J Med 2015；373：1021–31.
[22] Piot C， Croisille P， Staat P， et al. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med. 2008；359：473–481.
, 百拇医药
[23] Chakrabarti AK， Feeney K， Abueg G， et al. Rational and design of the EMBRACE STEMI Study： a phase 2a， randomized， double-blind， placebo-controlled trial to evaluate the safety， tolerability and efficacy of intravenous Bendavia on reperfu-sion injury in patients treated with standard therapy including primary percuta-neous coronary intervention and stenting for ST-segment elevation myocardial infarction. Am Heart J. 2013；165：509–514.
[24] Lonborg J， Vejlstrup N， Kelbaek H， et al. Exenatide rescues reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur Heart J. 2013；33： 1491–1499.
, 百拇医药
[25] Atar D， Petzelbauer P， Schwitter J， et al. Effects of intravenous FX06 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction results of the F.I.R.E. (Efficacy of FX06 in the Prevention of Myocardial Reperfusion Injury) trial. J Am Coll Cardiol. 2009；53(8)：720–729.
[26] Zeymer U， Suryapranata H， Monassier JP， et al. The Na+/H+ exchange inhibitor Eniporide as an adjunct to early reperfusion therapy for acute myocardial infarction. Results of the evaluation of the safety and cardio-protective effects of eniporide in acute myocardial infarction (ESCAMI) TRIAL. J Am Coll Cardiol. 2001；38(6)：1644–1650., 百拇医药(高杰张传焕)
[17] Zhao YJ， Fu XH， Ma XX， et al. Intracoronary fixed dose nitroprusside via thrombus aspiration catheter for the prevention of the no-reflow phenomenon following primary percutaneous coronary intervention in acute myocardial infarction.Exp Ther Med 2013；6：479–84.
, 百拇医药
[18] Nazir SA， Khan JN， Mahmoud IZ， et al. The REFLO-STEMI trial comparing intracoronary adenosine， sodium nitroprusside and standard therapy for the attenuation of infarct size and microvascular obstruction during primary percutaneous coronary intervention： study protocol for a randomised controlled trial. Trials 2014；15：371.
[19] Akpek M，Sahin O，Sarli B，et al.Acute Effects of Intracoronary Tirofiban on No-Reflow Phenomena in Patients With ST-Segment Elevated Myocardial InfarctionUndergoing Primary Percutaneous Coronary Intervention[J].Angiology，2015，66(6)：560-567
, 百拇医药
[20] Iwakura J， Ito H， Okamura A， et al. Nicorandil treatment in patients with acute myocardial infarction： a meta-analysis. Circ J 2009；73：925–31.
[21] Cung TT， Morel O， Cayla G， et al. Cyclosporine before PCI in patients with acute myocardial infarction. N Engl J Med 2015；373：1021–31.
[22] Piot C， Croisille P， Staat P， et al. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med. 2008；359：473–481.
, 百拇医药
[23] Chakrabarti AK， Feeney K， Abueg G， et al. Rational and design of the EMBRACE STEMI Study： a phase 2a， randomized， double-blind， placebo-controlled trial to evaluate the safety， tolerability and efficacy of intravenous Bendavia on reperfu-sion injury in patients treated with standard therapy including primary percuta-neous coronary intervention and stenting for ST-segment elevation myocardial infarction. Am Heart J. 2013；165：509–514.
[24] Lonborg J， Vejlstrup N， Kelbaek H， et al. Exenatide rescues reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur Heart J. 2013；33： 1491–1499.
, 百拇医药
[25] Atar D， Petzelbauer P， Schwitter J， et al. Effects of intravenous FX06 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction results of the F.I.R.E. (Efficacy of FX06 in the Prevention of Myocardial Reperfusion Injury) trial. J Am Coll Cardiol. 2009；53(8)：720–729.
[26] Zeymer U， Suryapranata H， Monassier JP， et al. The Na+/H+ exchange inhibitor Eniporide as an adjunct to early reperfusion therapy for acute myocardial infarction. Results of the evaluation of the safety and cardio-protective effects of eniporide in acute myocardial infarction (ESCAMI) TRIAL. J Am Coll Cardiol. 2001；38(6)：1644–1650., 百拇医药(高杰张传焕)